KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Accounts Payables (2016 - 2025)

Pacira BioSciences has reported Accounts Payables over the past 16 years, most recently at $15.2 million for Q4 2025.

  • Quarterly results put Accounts Payables at $15.2 million for Q4 2025, down 20.82% from a year ago — trailing twelve months through Dec 2025 was $15.2 million (down 20.82% YoY), and the annual figure for FY2025 was $15.2 million, down 20.82%.
  • Accounts Payables for Q4 2025 was $15.2 million at Pacira BioSciences, down from $17.7 million in the prior quarter.
  • Over the last five years, Accounts Payables for PCRX hit a ceiling of $30.1 million in Q2 2025 and a floor of $7.9 million in Q3 2021.
  • Median Accounts Payables over the past 5 years was $15.5 million (2022), compared with a mean of $16.1 million.
  • Biggest five-year swings in Accounts Payables: plummeted 47.96% in 2024 and later skyrocketed 157.98% in 2025.
  • Pacira BioSciences' Accounts Payables stood at $10.5 million in 2021, then soared by 44.36% to $15.2 million in 2022, then rose by 3.14% to $15.7 million in 2023, then grew by 21.88% to $19.1 million in 2024, then dropped by 20.82% to $15.2 million in 2025.
  • The last three reported values for Accounts Payables were $15.2 million (Q4 2025), $17.7 million (Q3 2025), and $30.1 million (Q2 2025) per Business Quant data.